Immunotherapy duo shows promise in early sarcoma trial
NCT ID NCT04420975
First seen Mar 24, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This early-phase study tests whether combining two immunotherapy drugs—nivolumab (given intravenously) and BO-112 (injected directly into the tumor)—before surgery is safe and effective for people with soft tissue sarcoma that can be surgically removed. About 14 adults with various sarcoma subtypes will receive the combination, then undergo surgery to remove the tumor. Researchers will monitor side effects and examine the removed tumor tissue to see how the immune system responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.